NPC1L1 and prostate carcinoma: We found that genetically proxied inhibition of HMG-CoA reductase and NPC1L1 but not PCSK9 were significantly associated with reduced risk of breast cancer (mainly ER-positive breast cancer), while only genetically determined PCSK9 inhibition was associated with low odds of prostate cancer.